These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 7575701)

  • 1. Quantitative bone scintigraphy in the management of monostotic Paget's disease of bone.
    Patel S; Pearson D; Hosking DJ
    Arthritis Rheum; 1995 Oct; 38(10):1506-12. PubMed ID: 7575701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Symptomatic and scintigraphic improvement after intravenous pamidronate treatment of Paget's disease of bone in patients with normal serum alkaline phosphatase levels.
    Ang G; Feiglin D; Moses AM
    Endocr Pract; 2003; 9(4):280-3. PubMed ID: 14561571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Usefulness of biochemical markers of bone turnover in assessing response to the treatment of Paget's disease.
    Alvarez L; Guañabens N; Peris P; Vidal S; Ros I; Monegal A; Bedini JL; Deulofeu R; Pons F; Muñoz-Gomez J; Ballesta AM
    Bone; 2001 Nov; 29(5):447-52. PubMed ID: 11704497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of intravenous pamidronate therapy on Paget's disease of bone.
    Bombassei GJ; Yocono M; Raisz LG
    Am J Med Sci; 1994 Oct; 308(4):226-33. PubMed ID: 7942981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenously administered pamidronate in the treatment of Paget's disease of bone.
    Tucci JR; Bontha S
    Endocr Pract; 2001; 7(6):423-9. PubMed ID: 11747277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone turnover markers in Paget's disease of the bone: A Systematic review and meta-analysis.
    Al Nofal AA; Altayar O; BenKhadra K; Qasim Agha OQ; Asi N; Nabhan M; Prokop LJ; Tebben P; Murad MH
    Osteoporos Int; 2015 Jul; 26(7):1875-91. PubMed ID: 26037791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of a whole body index with bone scintigraphy to monitor the response to therapy in Paget's disease.
    Griffith K; Pearson D; Parker C; Thorpe S; Vincent RM; Hosking DJ
    Nucl Med Commun; 2001 Oct; 22(10):1069-75. PubMed ID: 11567178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of bisphosphonate treatment in patients with Paget's disease of the skull.
    Donáth J; Krasznai M; Fornet B; Gergely P; Poór G
    Rheumatology (Oxford); 2004 Jan; 43(1):89-94. PubMed ID: 12923287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Is beta 2-microglobulin a marker of bone remodeling in Paget's disease of bone?].
    Wilczek H
    Cas Lek Cesk; 1997 Dec; 136(23):730-2. PubMed ID: 9476376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Three phase 99Tcm (V)DMSA scintigraphy in Paget's disease: an indicator of pamidronate effect.
    Kobayashi H; Shigeno C; Sakahara H; Yamamoto T; Hosono M; Fujimoto R; Konishi J
    Br J Radiol; 1997 Oct; 70(838):1056-9. PubMed ID: 9404211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum osteoprotegerin and its ligand in Paget's disease of bone: relationship to disease activity and effect of treatment with bisphosphonates.
    Alvarez L; Peris P; Guañabens N; Vidal S; Ros I; Pons F; Filella X; Monegal A; Muñoz-Gomez J; Ballesta AM
    Arthritis Rheum; 2003 Mar; 48(3):824-8. PubMed ID: 12632438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of Paget's disease of bone with single dose intravenous pamidronate.
    Watts RA; Skingle SJ; Bhambhani MM; Pountain G; Crisp AJ
    Ann Rheum Dis; 1993 Aug; 52(8):616-8. PubMed ID: 8215628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in serum HDL and LDL cholesterol in patients with Paget's bone disease treated with pamidronate.
    Montagnani A; Gonnelli S; Cepollaro C; Campagna MS; Franci MB; Pacini S; Gennari C
    Bone; 2003 Jan; 32(1):15-9. PubMed ID: 12584031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Term Bone Scintigraphy Results After Intravenous Zoledronate in Paget's Disease of Bone.
    Reid IR; Maslowski K
    Calcif Tissue Int; 2017 Jul; 101(1):43-49. PubMed ID: 28324123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment with tiludronate has a similar effect to risedronate on Paget's disease activity assessed by bone markers and bone scintigraphy.
    Peris P; Alvarez L; Vidal S; Martínez MA; Monegal A; Guañabens N
    Clin Exp Rheumatol; 2007; 25(2):206-10. PubMed ID: 17543143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose pamidronate in the management of resistant Paget's disease.
    Cundy T; Wattie D; King AR
    Calcif Tissue Int; 1996 Jan; 58(1):6-8. PubMed ID: 8825232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two cases of monostotic Paget's disease: effects of bisphosphonate.
    Hoshiro M; Harada T; Iwai H; Miyatake T; Nishimura A; Ohno Y; Aoki N
    Endocr J; 2003 Aug; 50(4):385-92. PubMed ID: 14599111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone scintigraphy following intravenous pamidronate for Paget's disease of bone.
    Ryan PJ; Gibson T; Fogelman I
    J Nucl Med; 1992 Sep; 33(9):1589-93. PubMed ID: 1517830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical experience with pamidronate in the treatment of Paget's disease of bone.
    Gallacher SJ; Boyce BF; Patel U; Jenkins A; Ralston SH; Boyle IT
    Ann Rheum Dis; 1991 Dec; 50(12):930-3. PubMed ID: 1768163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget's disease of bone.
    Walsh JP; Ward LC; Stewart GO; Will RK; Criddle RA; Prince RL; Stuckey BG; Dhaliwal SS; Bhagat CI; Retallack RW; Kent GN; Drury PJ; Vasikaran S; Gutteridge DH
    Bone; 2004 Apr; 34(4):747-54. PubMed ID: 15050907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.